InsiderClue
← All stocks

Spyre Therapeutics, Inc.

SYRE Mostly scheduled
CIK 0001636282 #969 in the set updated 17 Sep 2026
Bought (120 mo)
$4.00M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$439.21M
$19.83M on a plan · $417.13M straight out of an exercise
Sold at will
$2.25M
9 of 90 sales
Net
−$435.21M
+$1.75M against sales at will

By person

17 insiders · 147 transactions
74.2×

Cameron Turtle holds 74.2 times base salary in stock. $49.37M of shares against $665.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Cameron Turtle last reported holding, valued at $89.35, the price Common Stock was last bought or sold at on the open market here, on 2 Sep 2026.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Fairmount Funds Management LLC entity
Director
—
$399.66M (1) scheduled
−$399.66M
0
0.0000%
$0.00
—
Turtle Cameron
Chief Executive Officer
—
$9.99M (34) scheduled
−$9.99M
552,540
0.6266%
$49.37M
+2,231%
HENDERSON MICHAEL THOMAS
Director
—
$7.95M (5) scheduled
−$7.95M
68,606
0.0778%
$6.13M
—
Burrows Scott L
Chief Financial Officer
—
$7.68M (22) scheduled
−$7.68M
79,762
0.0905%
$7.13M
—
Sloan Sheldon
Chief Medical Officer
—
$7.35M (11) scheduled
−$7.35M
0
0.0000%
$0.00
—
Albers Jeffrey W.
Director
—
$2.66M (5) scheduled
−$2.66M
9,360
0.0106%
$836.32K
−72.8%
King-Jones Heidy
See Remarks
—
$2.48M (5) scheduled
−$2.48M
2,845
0.0032%
$254.20K
0.0%
Quinn Anthony G.
President & CEO
$2.10M (25)
—
+$2.10M
550,540
0.6244%
$49.19M
—
Novartis Bioventures Ltd entity
10% owner
—
$1.37M (5)
−$1.37M
2,175,314
2.47%
$194.36M
−5.9%
Alspaugh Jonathan
President and CFO
$604.66K (5)
—
+$604.66K
165,372
0.1876%
$14.78M
—
ORBIMED ADVISORS LLC entity
10% owner
$563.88K (3)
—
+$563.88K
1,469,524
1.67%
$131.30M
+8.0%
Shanafelt Armen
Director
$549.69K (3)
—
+$549.69K
150,000
0.1701%
$13.40M
—
York Charles N II
Chief Financial Officer and VP
$108.25K (5)
—
+$108.25K
34,787
0.0395%
$3.11M
+221.3%
Schuchart Aaron
Chief Business Officer
—
$57.01K (2)
−$57.01K
2,500
0.0028%
$223.38K
—
Souza Marcio
Director
$50.47K (1)
—
+$50.47K
90,000
0.1021%
$8.04M
—
Hanley Jr. Michael Conick
Chief Business Officer
$20.02K (1)
—
+$20.02K
36,200
0.0411%
$3.23M
+352.5%
GEORGIOU GEORGE
Director
—
—
—
175,861
0.1994%
$15.71M
+26.9%

Individual transactions

43
Insider
Date
Role
Action
Shares
Price
Amount
Souza Marcio
25 Aug 2022
Director
Buy
90,000
$0.56
$50.47K
Hanley Jr. Michael Conick
8 Jun 2022
Chief Commercial Officer
Buy
28,200
$0.71
$20.02K
Quinn Anthony G.
16 Mar 2022
President & CEO
Buy
80,079
$2.34
$187.71K
Quinn Anthony G.
15 Mar 2022
President & CEO
Buy
42,417
$1.86
$78.94K
Quinn Anthony G.
14 Mar 2022
President & CEO
Buy
67,472
$1.93
$130.22K
Alspaugh Jonathan
11 Mar 2022
Chief Financial Officer
Buy
75,000
$2.08
$156.00K
Quinn Anthony G.
11 Mar 2022
President & CEO
Buy
34,777
$2.06
$71.78K
Shanafelt Armen
13 Dec 2021
Director
Buy
14,685
$3.65
$53.60K
Quinn Anthony G.
10 Dec 2021
President & CEO
Buy
10,526
$3.75
$39.47K
Shanafelt Armen
10 Dec 2021
Director
Buy
13,516
$3.65
$49.33K
Alspaugh Jonathan
9 Dec 2021
Chief Financial Officer
Buy
50,000
$3.72
$186.00K
Quinn Anthony G.
9 Dec 2021
President & CEO
Buy
43,108
$3.70
$159.50K
Shanafelt Armen
9 Dec 2021
Director
Buy
121,799
$3.67
$446.76K
Alspaugh Jonathan
18 Aug 2021
Chief Financial Officer
Buy
7,200
$6.72
$48.40K
Alspaugh Jonathan
17 Aug 2021
Chief Financial Officer
Buy
23,392
$6.50
$151.98K
Alspaugh Jonathan
16 Aug 2021
Chief Financial Officer
Buy
9,780
$6.37
$62.28K
Quinn Anthony G.
30 Apr 2020
President & CEO
Buy
165,000
$4.75
$783.75K
Quinn Anthony G.
14 Jun 2019
President & CEO
Buy
5,282
$6.23
$32.91K
Quinn Anthony G.
13 Jun 2019
President & CEO
Buy
14,406
$6.17
$88.84K
Quinn Anthony G.
12 Jun 2019
President & CEO
Buy
12,217
$6.11
$74.70K
Quinn Anthony G.
22 May 2019
President & CEO
Buy
3,809
$6.86
$26.13K
Quinn Anthony G.
21 May 2019
President & CEO
Buy
13,794
$6.89
$94.98K
Quinn Anthony G.
20 May 2019
President & CEO
Buy
8,989
$6.56
$58.92K
Quinn Anthony G.
17 May 2019
President & CEO
Buy
6,218
$6.65
$41.34K
Quinn Anthony G.
16 May 2019
President & CEO
Buy
5,520
$6.83
$37.69K
Quinn Anthony G.
15 May 2019
President & CEO
Buy
6,256
$6.76
$42.27K
Quinn Anthony G.
15 Feb 2019
President & CEO
Buy
719
$7.10
$5.10K
Quinn Anthony G.
15 Aug 2018
President & CEO
Buy
994
$9.13
$9.08K
Quinn Anthony G.
15 Feb 2018
President & CEO
Buy
2,000
$6.02
$12.04K
Quinn Anthony G.
8 Dec 2017
Interim CEO
Buy
600
$5.07
$3.04K
Quinn Anthony G.
7 Dec 2017
Interim CEO
Buy
2,800
$4.99
$13.97K
Quinn Anthony G.
6 Dec 2017
Interim CEO
Buy
4,888
$4.92
$24.07K
Quinn Anthony G.
5 Dec 2017
Director
Buy
5,065
$4.93
$24.98K
York Charles N II
5 Dec 2017
Chief Financial Officer and VP
Buy
10,241
$4.76
$48.70K
Quinn Anthony G.
4 Dec 2017
Director
Buy
7,956
$4.98
$39.62K
York Charles N II
4 Dec 2017
Chief Financial Officer and VP
Buy
3,259
$4.97
$16.20K
Quinn Anthony G.
1 Dec 2017
Director
Buy
4,100
$4.53
$18.58K
York Charles N II
1 Dec 2017
Chief Financial Officer and VP
Buy
6,500
$4.59
$29.86K
York Charles N II
15 Aug 2017
Chief Financial Officer and VP
Buy
1,959
$2.52
$4.93K
ORBIMED ADVISORS LLC
21 Feb 2017
10% owner
Buy indirect
7,000
$5.36
$37.52K
ORBIMED ADVISORS LLC
17 Feb 2017
10% owner
Buy indirect
71,800
$5.19
$372.64K
ORBIMED ADVISORS LLC
16 Feb 2017
10% owner
Buy indirect
30,500
$5.04
$153.72K
York Charles N II
15 Feb 2017
Chief Financial Officer and VP
Buy
2,000
$4.28
$8.57K
Show all 147 transactions →

What was left out

Form 4 filings counted 202
Amendments (4/A) skipped 1
Filings about a different issuer 0
Unreadable filings 0
Joint filings 14
Sales on a Rule 10b5-1 plan 42
Sales straight out of an exercise 39
Sales at will 9
Transactions with no price 0
Shares from compensation/vesting 13,522,780
Sales filed before the plan box existed 7
History held since 16 Feb 2017